Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP-G28
- Development stage
- Discontinued
- Lead developer
- Qualigen Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
RP-G28 is a novel, ultra-purified, high-concentration galacto-oligosaccharide (GOS) developed as an orally administered microbiome modulator for the treatment of lactose intolerance. Its mechanism of action involves promoting the growth and abundance of lactose-fermenting bacteria such as *Bifidobacterium* and *Lactobacillus* in the gut. This shift in gut microbiota enhances colonic adaptation to lactose by increasing bacterial fermentation capacity, thereby reducing undigested lactose in the colon and alleviating symptoms like abdominal pain, bloating, gas, and diarrhea associated with lactose intolerance. Clinical trials have shown that RP-G28 significantly reduces symptoms of lactose intolerance and improves milk/dairy consumption and quality of life for patients. The drug was originally developed by Ritter Pharmaceuticals (now part of Qualigen Therapeutics), with additional development contributions from the University of British Columbia[1][2][3][4][5][6].
- Other names
- galacto-oligosaccharideGOS
Beyond the preview
Go deeper on RP-G28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP-G28.